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1. Introduction  
Most Alport cases, 85%, are caused by mutations in the X-linked gene, COL4A5 that encodes 
the α5 chain of type IV collagen, the most abundant structural protein in the glomerular 
basement membrane (GBM). The remaining 15% of cases are caused by autosomal recessive 
mutations in the genes that encode the α3 and α4 chains of the type IV collagen, 
COL4A3/COL4A4 1,2. Thin basement membrane nephropathy (TBMN) is reportedly also a 
genetically heterogeneous condition, caused by heterozygous COL4A3/COL4A4 mutations 
in about 40-50% of the cases. No other responsible genes have been identified as yet. 
Collagen type IV, as all collagens, is a trimer formed by combinations of three of the six 
alpha chains, α1-α6. Genes COL4A1 and COL4A2 map to chromosome 13q34, COL4A3 and 
COL4A4 map to chromosome 2q36–q37 and COL4A5 and COL4A6 map to Xq22-23. All six 
genes are encoded in nearly 50 exons and close to 1600 aminoacids, and consist of an N-
terminal 7S domain, a C-terminal non-collagenous (NC1) domain and a large collagenous 
domain in between, containing the characteristic Gly-X-Y repeat, common to all collagens. 
All six alpha chains contain 22-26 natural interruptions of the Gly-X-Y repeats, spread 
throughout their central collagenous domain. These are presumably regions of specific 
function and/or ligand binding sequences, of significance to its structural role in the 
basement membrane. Although there are many possible combinations among the six alpha 
chains, only three are biologically compatible and found in basement membranes. These are 
composed of α1α1α2, α3α4α5 and α5α5α6. Type IV collagen participates in forming 
networks interacting with additional important components of the basement membranes, 
such as laminin and nidogen 3,4. As a component of the glomerular filtration barrier, along 
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with the endothelial cells and the podocytes, basement membranes play a crucial role as a 
selective filter, based on molecular size and charge. A damage of the basement membrane or 
inherited defects such as mutations in type IV collagen lead to the abnormal passage of red 
blood cells in the urine. Mutations in five of the six COL4A chains have been linked to 
specific phenotypes (Table 1). 
 
Chain Gene Chromosome Disease association References 
α1(IV) COL4A1 13q34 
Porencephaly; Brain small vessel disease with 
hemorrhage;  autosomal dominant hereditary 
angiopathy with nephropathy, aneurysms, and 
muscle cramps (HANAC syndrome) 
20-22 
α2(IV) COL4A2 13q34 None  
α3(IV) COL4A3 2q36–q37 
Autosomal Recessive Alport Syndrome;  
Autosomal Dominant Alport Syndrome; Benign 
Familial Hematuria and Thin Basement 
Membrane Nephropathy; Thin Basement 
Membrane Nephropathy associated with Focal 
Segmental Glomerulosclerosis 
1, 9, 23, 24 
α4(IV) COL4A4 2q36–q37 
Autosomal Recessive Alport Syndrome;  
Autosomal Dominant Alport Syndrome; Benign 
Familial Hematuria and Thin Basement 
Membrane Nephropathy; Thin Basement 
Membrane Nephropathy associated with Focal 
Segmental Glomerulosclerosis 
1, 9, 25, 26 
α5(IV) COL4A5 Xq22-23 X-liked Alport Syndrome 27 
α6(IV) COL4A6 Xq22-23 
X-liked Alport Syndrome with Diffuse 
Leiomyomatosis 
(Contiguous Gene Syndrome) 
28 
Table 1. Type IV collagen chains, genes, chromosomal locations and related diseases. 
2. Familial microscopic hematuria 
In view of the Case we are presenting in the next section, it is worth discussing the issue of 
microscopic hematuria as the presenting symptom of patients with TBMN due to 
heterozygous mutations in the collagen IV genes. According to some older publications, 
these patients occasionally progress to proteinuria and chronic kidney disease (CKD) while 
a small percentage reach end-stage kidney disease (ESKD) on long follow-up 5-8. In a paper 
we published in 2007, we presented our initial experience in investigating 116 patients of 13 
Cypriot families, where 20 renal biopsies had the dual diagnosis of focal segmental 
glomerulosclerosis (FSGS) and TBMN. These families segregated microscopic hematuria, 
mild proteinuria and CKD of variable severity, including several patients with ESKD. 
Initially, we searched with no success, for mutations in genes responsible for primary 
autosomal dominant FSGS, such as ACTN4 (α-actinin 4) and CD2AP that were known and 
cloned at the time 9. After some lengthy molecular investigations and new ideas, we ended 
up discovering that all patients who had FSGS on biopsy as well as many others in the same 
families, had heterozygous mutations in the COL4A3 or COL4A4 genes, which when 
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inherited in homozygosity or compound heterozygosity cause the classic autosomal form of 
Alport syndrome. In fact in one of our families, two patients developed classical Alport 
syndrome, as compound heterozygotes, after they inherited two mutations, one from each 
parent (G1334E/G871C) 9. 
In heterozygous patients, this dual diagnosis of TBMN and FSGS in the presence of CKD could 
not be easily explained. However this work established that under certain circumstances that 
are not so uncommon, several such patients do not remain with only familial benign 
microscopic hematuria that offers excellent renal prognosis but rather after the age of 40-50, 
some of them progress to CKD and ESKD. Long follow-up is the norm in our setting in 
Cyprus, where owing to the small population and the limited number of nephrology centers 
(six in total, including one pediatric nephrology clinic), the patients are attended by a small 
number of experts over several decades. Our current data of 180 patients reveal that nearly 
50% of patients at all ages develop additional proteinuria with some degree of CKD, while 
21% progress to ESKD (25% of all patients >50-yo) perhaps owing to the confounding role of 
modifier gene(s). These data cast doubt on the correctness of the belief that the diagnosis of 
TBMN, in patients who are heterozygous carriers of mutations in the COL4A3/COL4A4 genes, 
is synonymous to "benign familial hematuria" with excellent renal prognosis. 
3. Case presentation 
In early 2008, a young Greek couple from Athens was referred to our laboratory with a clinical 
situation summarized as follows: The proband, individual III-2 in Figure 1A, was married and 
interested in having children. She and her husband asked for appropriate investigations 
aiming, if possible, to have an antenatal test, in order to avoid having children who might 
develop ESKD like her father. On her father’s side there was no previous easily diagnosed 
history for a familial renal disease. Her father II-1, had presented in a London hospital in 1991, 
at age 46 years, with persistent microscopic hematuria, proteinuria 3.3g/day, hypertension on 
treatment with Enalapril, and with chronic renal failure, as evidenced by elevated serum 
creatinine and urea levels. The attending nephrologist estimated his creatinine clearance at 40-
50 ml/min. A renal biopsy showed early glomerulo-sclerosis and uniform thinning of the 
GBM on EM that also included focal splitting. In the report, the diagnosis of possible 
hereditary Alport nephritis was discussed but it was not certain. He reached ESKD, four years 
later, at 50 and was transplanted at 52-yo, still with no deafness. The proband and her older 
sister had microscopic hematuria since childhood. In addition to microscopic hematuria, the 
proband’s sister, III-1, had proteinuria. The proband’s mother was healthy. The paternal uncle, 
subject II-3, had proteinuria of 2g/day, reduced GFR and elevated plasma creatinine at 2.8 
mg/dl, with normal hearing which remained normal until the age of 54 when the last 
information is available. He also underwent a renal biopsy at age 45 years, which was 
compatible with focal and segmental glomerulosclerosis but no EM results were available. The 
proband’s paternal grand-mother, subject I-2, was diagnosed with mild renal failure at age 76-
yo, when she was evaluated and was refused to serve as a living kidney donor to her son. Her 
findings could not be properly evaluated and were attributed at the time to a familial 
condition or age related. The proband had been a competitive swimmer during adolescence 
and had studied physical education, something that initially prompted her nephrologist in 
Greece to attribute her microscopic hematuria to her extreme physical activities. Because of the 
above uncertain family history, the proband sought professional counselling and inquired 
about the prospects of molecular genetics helping her reach a correct diagnosis. At the same 
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time she and her husband were interested in undergoing a prenatal diagnosis in order to 
minimize the likelihood of bearing an affected child. 
 
 
Fig. 1. A: Pedigree with relevant clinical information of the subjects under study. Note that 
the overall clinical scenario does not support a clear-cut X-linked or autosomal inheritance 
pattern. 
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4. Differential diagnosis 
Even though the X-linked Alport syndrome was a reasonable suspicion, the attending 
nephrologist in Greece was not in a position to support this diagnosis unequivocally. The 
biopsy histological picture and the EM findings of diffuse thinning of the GBM in particular, 
the absence of deafness as well as the very late age of onset of ESKD of the proband’s father 
were not supportive of the classic adolescence onset X-linked Alport, as known in the early 
1990’s. This uncertainty was strengthened by the similar and even milder clinical course of 
his brother. The diagnosis was rather on the borderline between X-linked Alport syndrome 
and the heterozygous autosomal recessive Alport syndrome that actually presents with 
TBMN and microscopic hematuria, and then on long follow-up may develop FSGS with 
progression to CKD and ESKD. This second scenario for TBMN as the primary diagnosis 
was supported by our recent publication at the time, where we showed that in a large cohort 
of patients with COL4A3/COL4A4 heterozygous mutations, a great percentage of patients 
can progress to CKD and/or ESKD with the need for hemodialysis or kidney 
transplantation, mostly around or after 50 years of age 9. Actually, our current data show 
that 21% of such patients at all ages progress to ESKD, most of them after the age of 50. 
The proband was interested in a prenatal diagnosis by molecular means, if possible. 
Therefore, considering that the molecular analysis of the implicated genes is costly and 
cumbersome some prerequisites had to be satisfied: 
a. Confirmation of the familial nature of the disease,  
b. a definite clinical diagnosis,  
c. the gene at fault had to be identified unequivocally,  
d. the germline mutation or the affected haplotype had to be identified, and  
e. a definite and unequivocal molecular test had to be developed. 
In view of the uncertainty of the clinical diagnosis, a genetic counseling session took place 
between the nephrologist, the gynecologist and the parents in Greece, and the geneticist in 
Cyprus, which resulted in the decision to investigate further the family with molecular 
tools, with the purpose of satisfying the above necessary criteria before proceeding to 
pregnancy and a molecular prenatal test. At the time, the only credible symptom that 
segregated in the family in a dominant fashion was the microscopic hematuria, with three 
patients in two generations. 
5. Molecular investigations 
In order to solve the diagnostic dilemma we were faced with and be able to perform a 
prenatal molecular diagnosis according to the couple’s desire, we used the molecular 
approach. To this end, we first performed classic DNA linkage analysis for the Xq22-23-
linked COL4A5 locus and the chromosome 2q36-37-linked COL4A3/COL4A4 locus.  
As shown in Figure 1B, 1C, we used four polymorphic microsatellite markers flanking  
the COL4A3/COL4A4 locus and four markers flanking the X-linked locus of COL4A5. Under 
the assumption that the two affected brothers, subject II-1 and subject II-3, had inherited  
the same disease, we saw that they had inherited from their parents two different 
haplotypes around the COL4A3/COL4A4 locus. The probability for this to happen is 25%  
but this serendipitous event assisted us in excluding this locus as being at fault. Please note 
that under either an autosomal dominant or autosomal recessive mode of inheritance, if  
the two brothers had inherited the same disease from their parents we expected them to 
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have at least one haplotype or two haplotypes, respectively, in common. In Figure 1C  
the analyses with the X-chromosome-linked markers show that both affected brothers, 
inherited the same haplotype from their mother which, as expected was passed on to the 
subject’s two daughters. Even though this data was not strong enough based on the 
uncertain clinical diagnosis, we interpreted it as exclusion of the 2q locus and probable 
linkage to the X-linked locus. 
 
 
Fig. 1. B: Pedigree with DNA linkage analysis results at locus 2q36-37 (COL4A3/COL4A4). 
Note that the two brothers, II-1 and II-3, have inherited different haplotypes from their 
parents, hence proving no linkage to this locus. 
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Fig. 1. C: Pedigree with DNA linkage analysis data for locus Xq22-23 (COL4A5). Note that 
these results are compatible with X-linked inheritance. 
We then engaged into re-sequencing the COL4A5 gene in patient II-1 by amplifying and 
sequencing all exons, including the splicing junctions and around 100 bp of flanking intronic 
regions. This sequencing revealed several polymorphic sites as well as a collagen mutation at 
position 624 that resulted in substitution of glycine by aspartic acid, G624D 10. This mutation 
had been previously reported by three other groups and it was known to be associated with a 
milder Alport Syndrome phenotype, something that supported the mild presentation in our 
family 11-13. Further molecular analysis for this mutation by polymerase chain reaction and 
restriction enzyme digestion showed that the two brothers II-1 and II-3 share this identical 
mutation which they have both inherited from their mother, individual I-2 in the pedigree 
(Figure 2). As expected, both daughters of subject II-1 inherited this mutation as they both 
inherited the X chromosome from their father. We now had a definite molecular test we could 
use for a prenatal diagnosis. We then communicated this information to the doctors and the 
couple and they went on with a pregnancy and a chorionic villous sampling at around ten 
weeks of gestation. Molecular testing was performed which showed that the foetus was a 
mutation-free male. The mother delivered a boy that on testing had no microscopic hematuria. 
No molecular analysis has been performed on the child yet. Approximately two years later the 
couple went on for a second pregnancy and a prenatal diagnosis showed again a healthy male. 
The pregnancy is still in progress. 
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Fig. 2. DNA amplification by polymerase chain reaction, followed by restriction digest with 
enzyme EcoRV and electrophoresis on 3% agarose gel. The mutation G624D introduces a 
recognition site for EcoRV. Samples in lanes 1, 3 are from normal subjects, lane 2 is from a 
heterozygous female and lane 4 is from a hemizygous male. The region amplified 
encompasses exon 25 where the mutation G624D is located. It is a substitution of aminoacid 
glycine by aspartate because of a G>A transition at the second position of codon 624. 
6. Ethical issues 
The issue of prenatal diagnosis is always a difficult one and should be accompanied by 
proper professional genetic counselling. The classic Alport Syndrome is supposed to be one 
of the most severe glomerular diseases usually leading to ESKD before 30 years of age. It is 
true however, that in addition to this so called juvenile onset disease, there is the adult type 
where patients develop CKD and reach ESKD at older ages 14,15. Based on current literature, 
this is certainly published and known by many experts; apparently though it has not 
become common knowledge to the average practising clinician. In addition to the family 
presented here we have identified five other families of Hellenic origin who share this same 
mutation, G624D, with a total of 13 male patients (unpublished results). Although the 
spectrum of clinical presentation is quite variable, the overall impression is that this 
mutation is a very mild one that leads to ESKD after the age of 40 years, even close to or 
after 50 years, in most cases. At the same time the EM studies do not show the classical 
thickening and lamellation of the usual X-linked Alport but extensive thinning of the GBM. 
Our findings agree with data presented in previous publications that identified this 
mutation in families from other populations 10-13. However, the uncertainty and anxiety that 
accompany at-risk members belonging to families with conditions like this cannot always be 
dealt adequately clinically. This anxiety in the family and the uncertainty as to whether they 
were dealing with an X-linked or autosomal disease and the possibility of bringing to life an 
affected child, had led them to terminate an earlier pregnancy where the foetus was a male 
one. We only became aware of this event after the successful birth of their healthy first child. 
The aborted embryo might have been an affected or a healthy male under the scenario of  
X-linked inheritance; alternatively the embryo might have been a healthy male carrying no 
mutation or a heterozygous male, under the scenario of autosomal inheritance.  
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7. Discussion-concluding remarks 
One cannot escape the conclusion that molecular genetics is an extremely powerful tool to 
use in present day clinical medicine. In another two families we had in Cyprus that 
segregated COL4A5 mutation P628L, none of the clinicians that cared for the patients had 
initially thought of X-linked Alport Syndrome. The variable expression, the very late onset 
of ESKD and the milder atypical symptoms of male and female patients, even in the 
presence of older patients with ESKD, did not prompt us to suspect at the beginning  
X-linked Alport syndrome. A renal biopsy in one patient established the presence of TBMN, 
thereby suggesting different explanations. Interestingly, the pedigree structure could not 
give a clear-cut information for X-linked or autosomal inheritance, considering that some 
females had symptoms of the disease 10. The symptoms in six female carriers included 
microscopic hematuria while two of them exhibited additional non-nephrotic proteinuria. 
Also, a renal biopsy of a 19-year-old female showed TBMN with FSGS. At this setting, 
perhaps a skin biopsy and immunostaining for collagen IV might be enlightening if the 
staining came out negative for the alpha 5 chain. No such biopsy was attempted. 
Molecular testing for the COL4A5 was attempted based on the inheritance of microscopic 
hematuria and exclusion of linkage to the chromosome 2 locus. It was only the molecular 
approach that established the diagnosis and enabled proper counselling and treatment to 
the concerned members. 
Another issue that complicates matters is the genetic heterogeneity observed in a number of 
diseases, including inherited kidney conditions. Molecular defects in more than one gene 
complicate things as it doubles or triples the effort and the cost for a definite diagnosis. 
Newer tools and more robust methods for gene re-sequencing are clearly making things 
easier. Next generation sequencing and exome sequencing aimed at analyzing specifically 
the coding exonic sequences, can accelerate COL4A3/COL4A4 screening in 1-2 weeks instead 
of the 8-12 months needed with the conventional methods in small laboratories 16. However, 
still not every routine clinical diagnostic or University research laboratory is equipped with 
or has easy access to this newer generation of technology and machinery. 
In conclusion, as regards the Alport Syndrome and mutations in one of the COL4 genes, one 
should be aware of a) the rare, milder cases of X-linked COL4A5, Alport syndrome that 
presents with TBMN and delayed ESKD in the 50’s and b) the late development of CKD and 
ESKD in patients with heterozygous COL4A3/COL4A4 mutations and TBMN, also referred 
to by some as autosomal dominant Alport. The spectrum of these collagen IV nephropathies 
extends from vary mild cases with isolated microscopic hematuria for life on one end, and 
patients reaching ESKD during adolescence on the other end. Professionals involved in 
offering treatment and genetic counselling should be aware of these wide scenarios and they 
should offer the best possible advice making use of all available tools of our generation, 
including molecular approaches. Finally, it should be realized that the aetiology of familial 
microscopic hematuria is even more heterogeneous genetically. Recently, another inherited 
glomerulopathy, CFHR5 nephropathy, was described by Gale et al (2010) 17 and Athanasiou 
et al (2011) 18 that is mainly characterized by isolated C3 deposits in the mesangium and the 
sub-endothelial GBM area of the glomerulous. This nephropathy presents usually in 
childhood with persistent microscopic hematuria and 25% of such patients also show 
episodes of macroscopic hematuria that usually follow upper respiratory tract infections. 
Mostly affected are the male patients who can also progress to CKD and ESKD at ages over 
30-40. Therefore, a useful algorithm is presented as a guideline for molecular testing of 
patients belonging to families segregating glomerular microscopic hematuria. A kidney or a 
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skin biopsy may be performed before or after the molecular analysis depending on the 
clinical status or disease progression of the patient, for histological evaluation 19 (Figure 3). 
 
 
Fig. 3. Algorithm for molecular testing of patients belonging to families segregating 
microscopic hematuria of glomerular origin. A histological evaluation via a skin or renal 
biopsy accompanied by immunostaining before or after molecular investigations are 
performed, may assist in the diagnosis or provide useful clues for the direction of molecular 
analysis. When a causative germinal mutation is identified, it becomes feasible to offer genetic 
counseling as well as a reliable molecular diagnosis and prenatal testing with much easier and 
mush less costly approaches (From ref. 19, with permission from Springer Publisher).  
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